Expression of HuR and Cyclooxygenase-2 in Nodular Fasciitis and Low-Grade Sarcoma: An Immunohistochemical Study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Nodular fasciitis is the most common reactive mesenchymal lesion to be misidentified as a type of sarcoma. HuR is an mRNA-binding protein that can stabilize cyclooxygenase-2 (COX-2) mRNA leading to COX-2 overexpression. The aim of this study is a comparison of the expressions of COX-2 and HuR and the relationships between their expressions and the clinicopathologicalparameters in nodular fasciitis and low-grade sarcoma. Methods: We measured the expression of HuR and COX-2 in 21 cases of nodular fasciitis and 37 cases of low-grade sarcoma using immunohistochemistry. Results: The frequency of cytoplasmic immunoreactivity for HuR was 5 of 21 cases of nodular fasciitis (23.8%) and 23 of 37 cases of low-grade sarcoma (62.1%) (p=.013). COX-2 expression was moderate or strong in nodular fasciitis (12/21, 57.1%) and in low-grade sarcoma (29/37, 78.4%) (p=.034). In addition, a significant difference existed between these two entities in terms of the relationship between moderate or strong COX-2 expression and HuR cytoplasmic immunoreactivity (p=.009). Moderate or strong COX-2 immunoreactivity correlated with nuclear (p=.016) or cytoplasmic HuR (p=.024) expression in low-grade sarcoma but not in nodular fasciitis. Conclusions: This study suggests that HuR and COX-2 expression may be useful to differentiate nodular fasciitis from low-grade sarcoma.
Abstract
Background: Nodular fasciitis is the most common reactive mesenchymal lesion to be misidentified as a type of sarcoma. HuR is an mRNA-binding protein that can stabilize cyclooxygenase-2 (COX-2) mRNA leading to COX-2 overexpression. The aim of this study is a comparison of the expressions of COX-2 and HuR and the relationships between their expressions and the clinicopathologicalparameters in nodular fasciitis and low-grade sarcoma. Methods: We measured the expression of HuR and COX-2 in 21 cases of nodular fasciitis and 37 cases of low-grade sarcoma using immunohistochemistry. Results: The frequency of cytoplasmic immunoreactivity for HuR was 5 of 21 cases of nodular fasciitis (23.8%) and 23 of 37 cases of low-grade sarcoma (62.1%) (p=.013). COX-2 expression was moderate or strong in nodular fasciitis (12/21, 57.1%) and in low-grade sarcoma (29/37, 78.4%) (p=.034). In addition, a significant difference existed between these two entities in terms of the relationship between moderate or strong COX-2 expression and HuR cytoplasmic immunoreactivity (p=.009). Moderate or strong COX-2 immunoreactivity correlated with nuclear (p=.016) or cytoplasmic HuR (p=.024) expression in low-grade sarcoma but not in nodular fasciitis. Conclusions: This study suggests that HuR and COX-2 expression may be useful to differentiate nodular fasciitis from low-grade sarcoma.
참고문헌 (22)
- Turini ME, "Cyclooxygenase-2: a therapeutic target", Annu Rev Med, 53, pp.35~57 (2002)
- Coussens LM, "Inflammation and cancer", Nature, 420, pp.860~867 (2002)
- Aoki T, "Expression of cyclooxygenase-2, Bcl-2 and Ki-67 in pleomorphic adenoma with special reference to tumor proliferation and apoptosis", Oral Oncol, 40, pp.954~959 (2004)
- Leung WK, "Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma", Int J Oncol, 23, pp.1317~1322 (2003)
- Pai R, "Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors", FASEB J, 17, pp.1640~1647 (2003)
- Eun Jeong Lee, "Cyclooxygenase-2 promotes cell proliferation, migration andinvasion in U2OS human osteosarcoma cells", Experimental and Molecular Medicine, 39(4), pp.469~476 (2007), 생화학분자생물학회
- Endo M, "Cyclooxygenase-2 overexpression associated with a poor prognosis in chondrosarcomas", Hum Pathol, 37, pp.471~476 (2006)
- Sutton KM, "Cyclooxygenase-2 expression in chondrosarcoma", Oncology, 66, pp.275~280 (2004)
- Guhaniyogi J, "Regulation of mRNA stability in mammalian cells", Gene, 265, pp.11~23 (2001)
- Dixon DA, "Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells", J Clin Invest, 108, pp.1657~1665 (2001)
- Do SI, "Expression of embryonic lethal abnormal vision (ELAV)-like protein HuR and cyclooxygenase-2 (COX-2) in Ewing sarcoma", Tumori, 94, pp.347~350 (2008)
- Sachs AB, "Messenger RNA degradation in eukaryotes", Cell, 74, pp.413~421 (1993)
- Nabors LB, "HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3’ untranslated regions of cytokine and angiogenic factor mRNAs", Cancer Res, 61, pp.2154~2161 (2001)
- Denkert C, "Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression", Cancer Res, 64, pp.189~195 (2004)
- Heinonen M, "Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma", Cancer Res, 65, pp.2157~2161 (2005)
- Lopez de Silanes I, "Role of the RNA-binding protein HuR in colon carcinogenesis", Oncogene, 22, pp.7146~7154 (2003)
- Erkinheimo TL, "Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma", Cancer Res, 63, pp.7591~7594 (2003)
- Cho NP, "Cytoplasmic HuR over-expression is associated with increased cyclooxygenase-2 expression in laryngeal squamous cell carcinomas", PATHOLOGY, 39, pp.545~550 (2007), TAYLOR & FRANCIS LTD
- Cho NP, "Overexpression of cyclooxygenase-2 correlates with cytoplasmic HuR expression in salivary mucoepidermoid carcinoma but not in pleomorphic adenoma", JOURNAL OF ORAL PATHOLOGY & MEDICINE, 36, pp.297~303 (2007), BLACKWELL PUBLISHING
- Ristimaki A, "Expression of cyclooxygenase-2 in human gastric carcinoma", Cancer Res, 57, pp.1276~1280 (1997)
- Erkinheimo TL, "Cytoplasmic HuR expression correlates with epithelial cancer cell but not with stromal cell cyclooxygenase-2 expression in mucinous ovarian carcinoma", Gynecol Oncol, 99, pp.14~19 (2005)
- , AUF-2, tristetraprolin, HuR (Hu antigen R) or FBP1 (far-upstream-sequence-element-binding protein 1), "Biochem J", 2004, 629~639